Literature DB >> 9279896

Can repeated plasma donation by asymptomatic HIV-infected individuals delay the onset of AIDS?

D R Bainbridge1, M W Lowdell, I M Hannet, K W Strauss, A Karpas.   

Abstract

Healthy HIV-positive regular donors of plasma in a programme of passive immunotherapy for AIDS patients were studied over a period of about two years. None developed symptoms of clinical progression; most seemed to make substantial gains of CD4 cells by comparison with asymptomatic individuals who were not donating. The effects of donation did not seem to diminish with repetition, and donor CD4 counts tended towards stabilizing within normal limits. Asymptomatic HIV-positive individuals were compared immunologically with 'normals' and people with AIDS, using a battery of 25 measurements on peripheral blood. The immunological profiles of donor and non-donor asymptomatics, indistinguishable at the start, became dissimilar: donors' profiles resembled AIDS less, non-donors became less like 'normal' and a few non-donor results could not be distinguished from AIDS. Improvement in the CD4 counts and amelioration of the immunological profile in donors provide prima facie evidence that plasmapheresis may be therapeutic for asymptomatic HIV-positive people. Further studies are justified.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9279896      PMCID: PMC1691967          DOI: 10.1098/rstb.1997.0060

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  32 in total

1.  Note on an exact treatment of contingency, goodness of fit and other problems of significance.

Authors:  G H FREEMAN; J H HALTON
Journal:  Biometrika       Date:  1951-06       Impact factor: 2.445

2.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.

Authors:  J M Coffin
Journal:  Science       Date:  1995-01-27       Impact factor: 47.728

3.  Age-related changes in human blood lymphocyte subpopulations. II. Varying kinetics of percentage and absolute count measurements.

Authors:  F Hulstaert; I Hannet; V Deneys; V Munhyeshuli; T Reichert; M De Bruyere; K Strauss
Journal:  Clin Immunol Immunopathol       Date:  1994-02

4.  CD8+ T lymphocyte-mediated inhibition of HIV-1 long terminal repeat transcription: a novel antiviral mechanism.

Authors:  C H Chen; K J Weinhold; J A Bartlett; D P Bolognesi; M L Greenberg
Journal:  AIDS Res Hum Retroviruses       Date:  1993-11       Impact factor: 2.205

5.  Passive hyperimmune plasma therapy in the treatment of acquired immunodeficiency syndrome: results of a 12-month multicenter double-blind controlled trial. The Passive Hyperimmune Therapy Study Group.

Authors:  J Levy; T Youvan; M L Lee
Journal:  Blood       Date:  1994-10-01       Impact factor: 22.113

6.  CD4+ lymphocyte response to zidovudine as a predictor of AIDS-free time and survival time.

Authors:  N M Graham; S Piantadosi; L P Park; J P Phair; C R Rinaldo; J L Fahey
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-11

7.  Rate of CD4 cell decline and prediction of survival in zidovudine-treated patients.

Authors:  P J Easterbrook; J Emami; B Gazzard
Journal:  AIDS       Date:  1993-10       Impact factor: 4.177

8.  Effect of cytokines on HIV replication in CD4+ lymphocytes: lack of identity with the CD8+ cell antiviral factor.

Authors:  C E Mackewicz; H Ortega; J A Levy
Journal:  Cell Immunol       Date:  1994-02       Impact factor: 4.868

9.  Virus burden in long-term survivors of human immunodeficiency virus (HIV) infection is a determinant of anti-HIV CD8+ lymphocyte activity.

Authors:  J Ferbas; A H Kaplan; M A Hausner; L E Hultin; J L Matud; Z Liu; D L Panicali; H Nerng-Ho; R Detels; J V Giorgi
Journal:  J Infect Dis       Date:  1995-08       Impact factor: 5.226

10.  Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma.

Authors:  D Vittecoq; S Chevret; L Morand-Joubert; F Heshmati; F Audat; M Bary; T Dusautoir; A Bismuth; J P Viard; F Barré-Sinoussi
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.